{‘She has no experience’: the American healthcare community girds for Høeg's appointment at the Food and Drug Administration.
Given that America continues making historic revisions to its vaccine recommendations, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccinations in the global health crisis and has focused upon possible deaths following Covid vaccination in her short time at the FDA.
Scheduled Changes to Childhood Vaccine Program
Public health authorities were set to reveal major changes to the childhood vaccine schedule recently, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US at odds with much of the world with no evidence for public health gain. This reveal has been delayed until the new year.
In place of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.
A New Direction at the Regulatory Body
The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.
Høeg has often pushed for discontinuing some pediatric shot schedules in the US so as to align more in line with Denmark's approach, a society with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.
To date public appearances, she has kept her attention on vaccines – typically the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.
Questions Over Background
Høeg has no apparent track record in pharmaceutical research, regulation or management, which has been customary for previous heads of the biologics center. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.
“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a major agency. She lacks background in industry regulation.”
Former directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who led the center have had.”
This division has an enormous workload at the FDA, Woodcock emphasized.
“The public just zeroes in on the novel medication approvals, but the generic program clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and every single one must be managed,” Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”
Furthermore, a substantial management component to the job, which supervises over 5,000 employees. “It’s a huge leadership role, if you do it right,” the former official said.
Response and Disputed Policies
In response to concerns about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among FDA leaders on immunizations, a press secretary responded that the “inquiries stem from incorrect presumptions”.
“Her experience aligns with the responsibilities of her job,” the spokesperson said, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.
As acting director, Dr. Høeg takes over the agency head's new priority voucher program, a contentious rapid drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being picked for this expedited pathway? Who is making the choices?” Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”
Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, except for shots.”
Documented Track Record on Immunizations
Regarding vaccines, Høeg has a clearer, if troubling, track record, critics have noted. She authored a study using unconfirmed public submissions to assess the frequency of myocarditis after COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.
Included in her “wish list” for the current government featured altering guidelines for novel immunizations and discontinuing “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Høeg has according to sources floated the idea of barring young men from obtaining Covid vaccines.
“She’s an all-around true believer who starts off with her beliefs and reverse-engineers to retrofit the data in a highly disingenuous, dishonest manner,” Howard argued.
Consolidating Power and a “Campaign of Retribution”
Dr. Høeg joined other contrarians, {like|
